Jin Medical International Ltd. (ZJYL) 10-Year Financial Performance & Capital Metrics

ZJYL • • Industrial / General

HealthcareMedical InstrumentsWound Care & Therapeutic DevicesSpecialized Therapeutic Devices

AboutJin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.Show more

Revenue $24M +18.6%
EBITDA $4M +28.8%
Net Income $4M +27.7%
EPS (Diluted) 0.02 +18.7%
Gross Margin 40.43% +18.1%
EBITDA Margin 16.96% +8.7%
Operating Margin 15.48% +7.0%
Net Margin 15.64% +7.7%
ROE 14% -4.7%
ROIC 10.26% -24.6%
Debt/Equity 0.41 +136.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Good 3Y average ROE of 15.7%
✓Healthy 5Y average net margin of 14.1%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y2.9%

3Y4.21%

TTM5.3%

Profit (Net Income) CAGR

10Y-

5Y0.16%

3Y11.78%

TTM-10.73%

EPS CAGR

10Y-

5Y20.89%

3Y33.85%

TTM-14.57%

ROCE

10Y Avg25.39%

5Y Avg17.22%

3Y Avg14.34%

Latest13.83%

Peer Comparison

Specialized Therapeutic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RMDResMed Inc.	38.05B	260.70	27.41	9.84%	27.35%	23.49%	4.37%	0.14
ZJYLJin Medical International Ltd.	22.54M	0.14	6.13	18.57%	10.94%	16.93%		0.41
FEMYFemasys Inc.	38.2M	0.64	-0.76	51.97%	-9.61%	-434.6%		3.23
NYXHNyxoah S.A.	221.59M	5.15	-2.85	3.98%	-14.85%	-164.31%		0.20
MLSSMilestone Scientific Inc.	22.8M	0.29	-4.91	-12.19%	-76.78%	-208.8%		0.06
NVCRNovoCure Limited	1.55B	13.80	-8.85	18.82%	-27.66%	-52.05%		1.90
EKSOEkso Bionics Holdings, Inc.	22.43M	8.55	-15.27	-1.94%	-70.74%	-107.8%		0.47
PLSEPulse Biosciences, Inc.	955.52M	14.10	-15.33		-868.99%	-80.62%		0.08

Profit & Loss

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Sales/Revenue+	20.91M	20.37M	16.19M	20.76M	19.19M	19.82M	23.5M
Revenue Growth %	-	-0.03%	-0.2%	0.28%	-0.08%	0.03%	0.19%
Cost of Goods Sold+	13.25M	12.86M	10.7M	14.4M	12.99M	13.04M	14M
COGS % of Revenue	0.63%	0.63%	0.66%	0.69%	0.68%	0.66%	0.6%
Gross Profit+	7.66M	7.51M	5.5M	6.36M	6.2M	6.78M	9.5M
Gross Margin %	0.37%	0.37%	0.34%	0.31%	0.32%	0.34%	0.4%
Gross Profit Growth %	-	-0.02%	-0.27%	0.16%	-0.03%	0.09%	0.4%
Operating Expenses+	3.33M	3.11M	3.14M	3.73M	4.07M	3.92M	5.86M
OpEx % of Revenue	0.16%	0.15%	0.19%	0.18%	0.21%	0.2%	0.25%
Selling, General & Admin	2.23M	1.98M	1.88M	2.16M	2.18M	2.37M	4.37M
SG&A % of Revenue	0.11%	0.1%	0.12%	0.1%	0.11%	0.12%	0.19%
Research & Development	1.2M	1.13M	1.26M	1.57M	1.89M	1.54M	1.5M
R&D % of Revenue	0.06%	0.06%	0.08%	0.08%	0.1%	0.08%	0.06%
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	4.23M	4.4M	2.35M	2.63M	2.13M	2.87M	3.64M
Operating Margin %	0.2%	0.22%	0.15%	0.13%	0.11%	0.14%	0.15%
Operating Income Growth %	-	0.04%	-0.47%	0.12%	-0.19%	0.35%	0.27%
EBITDA+	4.6M	4.75M	2.68M	2.97M	2.49M	3.09M	3.98M
EBITDA Margin %	0.22%	0.23%	0.17%	0.14%	0.13%	0.16%	0.17%
EBITDA Growth %	-	0.03%	-0.44%	0.11%	-0.16%	0.24%	0.29%
D&A (Non-Cash Add-back)	368.26K	344.04K	324.93K	341.25K	357.27K	225.9K	346.13K
EBIT	4.23M	4.4M	2.47M	2.89M	2.74M	2.87M	3.64M
Net Interest Income+	0	0	-112.4K	-9.49K	181.6K	182.68K	466.52K
Interest Income	25.24K	0	0	0	181.6K	182.68K	466.52K
Interest Expense	0	22.85K	112.4K	9.49K	0	0	0
Other Income/Expense	71.02K	-276.61K	-1.52K	248.84K	612.11K	354.68K	544.97K
Pretax Income+	4.3M	4.13M	2.35M	2.88M	2.74M	3.22M	4.18M
Pretax Margin %	0.21%	0.2%	0.15%	0.14%	0.14%	0.16%	0.18%
Income Tax+	616.88K	479.63K	147.15K	248.64K	36.11K	343.71K	763.88K
Effective Tax Rate %	0.86%	0.88%	0.94%	0.91%	0.99%	0.89%	0.88%
Net Income+	3.68M	3.65M	2.21M	2.63M	2.71M	2.88M	3.68M
Net Margin %	0.18%	0.18%	0.14%	0.13%	0.14%	0.15%	0.16%
Net Income Growth %	-	-0.01%	-0.4%	0.19%	0.03%	0.06%	0.28%
Net Income (Continuing)	3.68M	3.65M	2.21M	2.63M	2.71M	2.88M	3.42M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	-262.72K
EPS (Diluted)+	0.01	0.01	0.01	0.01	0.02	0.02	0.02
EPS Growth %	-	-	-	-	-	-0.01%	0.19%
EPS (Basic)	0.01	0.01	0.01	0.01	0.02	0.02	0.02
Diluted Shares Outstanding	400M	400M	400M	267.5M	135M	145.14M	156.47M
Basic Shares Outstanding	400.01M	400.12M	400.22M	267.57M	135.02M	145.14M	156.48M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Total Current Assets+	15.61M	17.7M	18.16M	19.42M	18.9M	31.12M	42.82M
Cash & Short-Term Investments	2.45M	3.34M	2.84M	5.73M	7.07M	16.7M	26.76M
Cash Only	853.3K	1.94M	1.66M	3.67M	4.79M	6.93M	8.14M
Short-Term Investments	1.6M	1.4M	1.18M	2.05M	2.28M	9.77M	18.62M
Accounts Receivable	6.34M	8.63M	7.86M	5.98M	4.25M	8.5M	8.78M
Days Sales Outstanding	110.7	154.59	177.19	105.11	80.87	156.53	136.29
Inventory	6.06M	5.74M	7.25M	7.04M	6.88M	5.86M	7.12M
Days Inventory Outstanding	166.91	162.85	247.51	178.44	193.31	163.98	185.58
Other Current Assets	745.95K	333.06K	-83.47K	523.47K	544.9K	60K	0
Total Non-Current Assets+	3.07M	2.66M	2.66M	2.48M	2.04M	1.79M	2.98M
Property, Plant & Equipment	2.74M	2.38M	2.31M	2.11M	1.63M	1.48M	1.72M
Fixed Asset Turnover	7.62x	8.57x	7.02x	9.83x	11.79x	13.39x	13.69x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	189.34K	177.29K	180.89K	185.1K	163.21K	154.36K	1.15M
Long-Term Investments	0	-177	-366.43K	0	-245	-152.47K	0
Other Non-Current Assets	140.16K	15.53K	366.43K	0	245	152.47K	0
Total Assets+	18.68M	20.36M	20.82M	21.9M	20.94M	32.9M	45.8M
Asset Turnover	1.12x	1.00x	0.78x	0.95x	0.92x	0.60x	0.51x
Asset Growth %	-	0.09%	0.02%	0.05%	-0.04%	0.57%	0.39%
Total Current Liabilities+	9.68M	9.66M	10.01M	7.87M	5.7M	8.92M	17.15M
Accounts Payable	7.75M	4.76M	5.43M	5.35M	4.11M	3.39M	3.01M
Days Payables Outstanding	213.31	135.18	185.45	135.61	115.57	94.94	78.54
Short-Term Debt	712.53K	2.87M	2.65M	0	0	4.11M	11.32M
Deferred Revenue (Current)	0	1000K	975.65K	1000K	830.3K	829.22K	797.08K
Other Current Liabilities	669.25K	1.56M	306.28K	0	366.16K	272.55K	0
Current Ratio	1.61x	1.83x	1.81x	2.47x	3.31x	3.49x	2.50x
Quick Ratio	0.99x	1.24x	1.09x	1.57x	2.11x	2.83x	2.08x
Cash Conversion Cycle	64.3	182.26	239.25	147.95	158.62	225.57	243.33
Total Non-Current Liabilities+	0	0	0	0	0	0	96.17K
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	96.17K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	9.68M	9.66M	10.01M	7.87M	5.7M	8.92M	17.25M
Total Debt+	712.53K	2.87M	2.65M	0	0	4.11M	11.6M
Net Debt	-140.77K	929.86K	983.72K	-3.67M	-4.79M	-2.82M	3.47M
Debt / Equity	0.08x	0.27x	0.25x	-	-	0.17x	0.41x
Debt / EBITDA	0.16x	0.60x	0.99x	-	-	1.33x	2.91x
Net Debt / EBITDA	-0.03x	0.20x	0.37x	-1.24x	-1.93x	-0.91x	0.87x
Interest Coverage	-	192.76x	20.95x	277.23x	-	-	-
Total Equity+	9M	10.71M	10.8M	14.03M	15.24M	23.98M	28.55M
Equity Growth %	-	0.19%	0.01%	0.3%	0.09%	0.57%	0.19%
Book Value per Share	0.02	0.03	0.03	0.05	0.11	0.17	0.18
Total Shareholders' Equity	9M	10.71M	10.8M	14.03M	15.24M	23.98M	28.82M
Common Stock	20K	20K	6.75K	6.75K	6.75K	7.8K	7.83K
Retained Earnings	4.87M	7.54M	9.6M	11.89M	14.41M	16.93M	20.02M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	461.44K	1.02M	1.11M	2.06M	740.29K	606.52K	2.04M
Minority Interest	0	0	0	0	0	0	-262.72K

Cash Flow

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Cash from Operations+	-2.39M	-1.33M	2.5M	5.84M	1.58M	3.11M	-1.21M
Operating CF Margin %	-0.11%	-0.07%	0.15%	0.28%	0.08%	0.16%	-0.05%
Operating CF Growth %	-	0.45%	2.89%	1.33%	-0.73%	0.97%	-1.39%
Net Income	3.68M	3.65M	2.21M	2.63M	2.71M	2.88M	3.42M
Depreciation & Amortization	368.26K	344.04K	329.91K	346.61K	362.6K	225.9K	346.13K
Stock-Based Compensation	0	0	0	0	0	0	0
Deferred Taxes	0	-30.36K	-77.92K	-1.66K	-86.02K	89.6K	36.33K
Other Non-Cash Items	569.69K	5.47M	80.05K	-91.31K	28.94K	113.48K	-89.93K
Working Capital Changes	-7.01M	-5.32M	-34.86K	2.96M	-1.43M	-200.81K	-4.92M
Change in Receivables	-3.97M	-2.21M	1.12M	3.08M	333.66K	-376.08K	-3.91M
Change in Inventory	-1.77M	248.34K	-1.37M	458.61K	-504.39K	1.56M	80.31K
Change in Payables	0	-2.79M	425.9K	-369.08K	-810.34K	-646.89K	-499.57K
Cash from Investing+	1.96M	126.94K	-1.96M	-1.07M	-120.9K	-7.73M	-9.51M
Capital Expenditures	-187.68K	-73.33K	-142.32K	-42.88K	-40.17K	-113.94K	-144.95K
CapEx % of Revenue	0.01%	0%	0.01%	0%	0%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	2.15M	54.85K	-2.1M	-215.03K	364.43K	10.14K	-978.93K
Cash from Financing+	-3.19M	2.36M	-343.91K	-2.87M	121.86K	6.91M	11.65M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	-3.19M	2.36M	11.42K	-103.88K	121.86K	-5.34M	4.48M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-2.58M	-1.4M	2.36M	5.8M	1.54M	2.99M	-2.33M
FCF Margin %	-0.12%	-0.07%	0.15%	0.28%	0.08%	0.15%	-0.1%
FCF Growth %	-	0.46%	2.69%	1.46%	-0.73%	0.94%	-1.78%
FCF per Share	-0.01	-0.00	0.01	0.02	0.01	0.02	-0.01
FCF Conversion (FCF/Net Income)	-0.65x	-0.36x	1.13x	2.22x	0.58x	1.08x	-0.33x
Interest Paid	0	0	136.55K	68.78K	0	5.32K	239.37K
Taxes Paid	0	0	522.11K	302.25K	47.44K	142.73K	205.37K

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	40.9%	37.02%	20.51%	21.2%	18.5%	14.68%	14%
Return on Invested Capital (ROIC)	35.78%	32.23%	15.08%	17.83%	15.36%	13.61%	10.26%
Gross Margin	36.62%	36.88%	33.95%	30.64%	32.3%	34.23%	40.43%
Net Margin	17.61%	17.91%	13.62%	12.67%	14.1%	14.52%	15.64%
Debt / Equity	0.08x	0.27x	0.25x	-	-	0.17x	0.41x
Interest Coverage	-	192.76x	20.95x	277.23x	-	-	-
FCF Conversion	-0.65x	-0.36x	1.13x	2.22x	0.58x	1.08x	-0.33x
Revenue Growth	-	-2.61%	-20.49%	28.22%	-7.58%	3.29%	18.57%

Frequently Asked Questions

Valuation & Price

Jin Medical International Ltd. (ZJYL) has a price-to-earnings (P/E) ratio of 6.1x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Jin Medical International Ltd. (ZJYL) reported $43.0M in revenue for fiscal year 2024. This represents a 105% increase from $20.9M in 2018.

Jin Medical International Ltd. (ZJYL) grew revenue by 18.6% over the past year. This is strong growth.

Yes, Jin Medical International Ltd. (ZJYL) is profitable, generating $4.7M in net income for fiscal year 2024 (15.6% net margin).

Dividend & Returns

Jin Medical International Ltd. (ZJYL) has a return on equity (ROE) of 14.0%. This is reasonable for most industries.

Jin Medical International Ltd. (ZJYL) had negative free cash flow of $0.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Jin Medical International Ltd. (ZJYL) 10-Year Financial Performance & Capital Metrics

ZJYL • • Industrial / General

HealthcareMedical InstrumentsWound Care & Therapeutic DevicesSpecialized Therapeutic Devices

Revenue $24M +18.6%
EBITDA $4M +28.8%
Net Income $4M +27.7%
EPS (Diluted) 0.02 +18.7%
Gross Margin 40.43% +18.1%
EBITDA Margin 16.96% +8.7%
Operating Margin 15.48% +7.0%
Net Margin 15.64% +7.7%
ROE 14% -4.7%
ROIC 10.26% -24.6%
Debt/Equity 0.41 +136.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Good 3Y average ROE of 15.7%
✓Healthy 5Y average net margin of 14.1%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y2.9%

3Y4.21%

TTM5.3%

Profit (Net Income) CAGR

10Y-

5Y0.16%

3Y11.78%

TTM-10.73%

EPS CAGR

10Y-

5Y20.89%

3Y33.85%

TTM-14.57%

ROCE

10Y Avg25.39%

5Y Avg17.22%

3Y Avg14.34%

Latest13.83%

Peer Comparison

Specialized Therapeutic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RMDResMed Inc.	38.05B	260.70	27.41	9.84%	27.35%	23.49%	4.37%	0.14
ZJYLJin Medical International Ltd.	22.54M	0.14	6.13	18.57%	10.94%	16.93%		0.41
FEMYFemasys Inc.	38.2M	0.64	-0.76	51.97%	-9.61%	-434.6%		3.23
NYXHNyxoah S.A.	221.59M	5.15	-2.85	3.98%	-14.85%	-164.31%		0.20
MLSSMilestone Scientific Inc.	22.8M	0.29	-4.91	-12.19%	-76.78%	-208.8%		0.06
NVCRNovoCure Limited	1.55B	13.80	-8.85	18.82%	-27.66%	-52.05%		1.90
EKSOEkso Bionics Holdings, Inc.	22.43M	8.55	-15.27	-1.94%	-70.74%	-107.8%		0.47
PLSEPulse Biosciences, Inc.	955.52M	14.10	-15.33		-868.99%	-80.62%		0.08

Profit & Loss

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Sales/Revenue+	20.91M	20.37M	16.19M	20.76M	19.19M	19.82M	23.5M
Revenue Growth %	-	-0.03%	-0.2%	0.28%	-0.08%	0.03%	0.19%
Cost of Goods Sold+	13.25M	12.86M	10.7M	14.4M	12.99M	13.04M	14M
COGS % of Revenue	0.63%	0.63%	0.66%	0.69%	0.68%	0.66%	0.6%
Gross Profit+	7.66M	7.51M	5.5M	6.36M	6.2M	6.78M	9.5M
Gross Margin %	0.37%	0.37%	0.34%	0.31%	0.32%	0.34%	0.4%
Gross Profit Growth %	-	-0.02%	-0.27%	0.16%	-0.03%	0.09%	0.4%
Operating Expenses+	3.33M	3.11M	3.14M	3.73M	4.07M	3.92M	5.86M
OpEx % of Revenue	0.16%	0.15%	0.19%	0.18%	0.21%	0.2%	0.25%
Selling, General & Admin	2.23M	1.98M	1.88M	2.16M	2.18M	2.37M	4.37M
SG&A % of Revenue	0.11%	0.1%	0.12%	0.1%	0.11%	0.12%	0.19%
Research & Development	1.2M	1.13M	1.26M	1.57M	1.89M	1.54M	1.5M
R&D % of Revenue	0.06%	0.06%	0.08%	0.08%	0.1%	0.08%	0.06%
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	4.23M	4.4M	2.35M	2.63M	2.13M	2.87M	3.64M
Operating Margin %	0.2%	0.22%	0.15%	0.13%	0.11%	0.14%	0.15%
Operating Income Growth %	-	0.04%	-0.47%	0.12%	-0.19%	0.35%	0.27%
EBITDA+	4.6M	4.75M	2.68M	2.97M	2.49M	3.09M	3.98M
EBITDA Margin %	0.22%	0.23%	0.17%	0.14%	0.13%	0.16%	0.17%
EBITDA Growth %	-	0.03%	-0.44%	0.11%	-0.16%	0.24%	0.29%
D&A (Non-Cash Add-back)	368.26K	344.04K	324.93K	341.25K	357.27K	225.9K	346.13K
EBIT	4.23M	4.4M	2.47M	2.89M	2.74M	2.87M	3.64M
Net Interest Income+	0	0	-112.4K	-9.49K	181.6K	182.68K	466.52K
Interest Income	25.24K	0	0	0	181.6K	182.68K	466.52K
Interest Expense	0	22.85K	112.4K	9.49K	0	0	0
Other Income/Expense	71.02K	-276.61K	-1.52K	248.84K	612.11K	354.68K	544.97K
Pretax Income+	4.3M	4.13M	2.35M	2.88M	2.74M	3.22M	4.18M
Pretax Margin %	0.21%	0.2%	0.15%	0.14%	0.14%	0.16%	0.18%
Income Tax+	616.88K	479.63K	147.15K	248.64K	36.11K	343.71K	763.88K
Effective Tax Rate %	0.86%	0.88%	0.94%	0.91%	0.99%	0.89%	0.88%
Net Income+	3.68M	3.65M	2.21M	2.63M	2.71M	2.88M	3.68M
Net Margin %	0.18%	0.18%	0.14%	0.13%	0.14%	0.15%	0.16%
Net Income Growth %	-	-0.01%	-0.4%	0.19%	0.03%	0.06%	0.28%
Net Income (Continuing)	3.68M	3.65M	2.21M	2.63M	2.71M	2.88M	3.42M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	-262.72K
EPS (Diluted)+	0.01	0.01	0.01	0.01	0.02	0.02	0.02
EPS Growth %	-	-	-	-	-	-0.01%	0.19%
EPS (Basic)	0.01	0.01	0.01	0.01	0.02	0.02	0.02
Diluted Shares Outstanding	400M	400M	400M	267.5M	135M	145.14M	156.47M
Basic Shares Outstanding	400.01M	400.12M	400.22M	267.57M	135.02M	145.14M	156.48M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Total Current Assets+	15.61M	17.7M	18.16M	19.42M	18.9M	31.12M	42.82M
Cash & Short-Term Investments	2.45M	3.34M	2.84M	5.73M	7.07M	16.7M	26.76M
Cash Only	853.3K	1.94M	1.66M	3.67M	4.79M	6.93M	8.14M
Short-Term Investments	1.6M	1.4M	1.18M	2.05M	2.28M	9.77M	18.62M
Accounts Receivable	6.34M	8.63M	7.86M	5.98M	4.25M	8.5M	8.78M
Days Sales Outstanding	110.7	154.59	177.19	105.11	80.87	156.53	136.29
Inventory	6.06M	5.74M	7.25M	7.04M	6.88M	5.86M	7.12M
Days Inventory Outstanding	166.91	162.85	247.51	178.44	193.31	163.98	185.58
Other Current Assets	745.95K	333.06K	-83.47K	523.47K	544.9K	60K	0
Total Non-Current Assets+	3.07M	2.66M	2.66M	2.48M	2.04M	1.79M	2.98M
Property, Plant & Equipment	2.74M	2.38M	2.31M	2.11M	1.63M	1.48M	1.72M
Fixed Asset Turnover	7.62x	8.57x	7.02x	9.83x	11.79x	13.39x	13.69x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	189.34K	177.29K	180.89K	185.1K	163.21K	154.36K	1.15M
Long-Term Investments	0	-177	-366.43K	0	-245	-152.47K	0
Other Non-Current Assets	140.16K	15.53K	366.43K	0	245	152.47K	0
Total Assets+	18.68M	20.36M	20.82M	21.9M	20.94M	32.9M	45.8M
Asset Turnover	1.12x	1.00x	0.78x	0.95x	0.92x	0.60x	0.51x
Asset Growth %	-	0.09%	0.02%	0.05%	-0.04%	0.57%	0.39%
Total Current Liabilities+	9.68M	9.66M	10.01M	7.87M	5.7M	8.92M	17.15M
Accounts Payable	7.75M	4.76M	5.43M	5.35M	4.11M	3.39M	3.01M
Days Payables Outstanding	213.31	135.18	185.45	135.61	115.57	94.94	78.54
Short-Term Debt	712.53K	2.87M	2.65M	0	0	4.11M	11.32M
Deferred Revenue (Current)	0	1000K	975.65K	1000K	830.3K	829.22K	797.08K
Other Current Liabilities	669.25K	1.56M	306.28K	0	366.16K	272.55K	0
Current Ratio	1.61x	1.83x	1.81x	2.47x	3.31x	3.49x	2.50x
Quick Ratio	0.99x	1.24x	1.09x	1.57x	2.11x	2.83x	2.08x
Cash Conversion Cycle	64.3	182.26	239.25	147.95	158.62	225.57	243.33
Total Non-Current Liabilities+	0	0	0	0	0	0	96.17K
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	96.17K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	9.68M	9.66M	10.01M	7.87M	5.7M	8.92M	17.25M
Total Debt+	712.53K	2.87M	2.65M	0	0	4.11M	11.6M
Net Debt	-140.77K	929.86K	983.72K	-3.67M	-4.79M	-2.82M	3.47M
Debt / Equity	0.08x	0.27x	0.25x	-	-	0.17x	0.41x
Debt / EBITDA	0.16x	0.60x	0.99x	-	-	1.33x	2.91x
Net Debt / EBITDA	-0.03x	0.20x	0.37x	-1.24x	-1.93x	-0.91x	0.87x
Interest Coverage	-	192.76x	20.95x	277.23x	-	-	-
Total Equity+	9M	10.71M	10.8M	14.03M	15.24M	23.98M	28.55M
Equity Growth %	-	0.19%	0.01%	0.3%	0.09%	0.57%	0.19%
Book Value per Share	0.02	0.03	0.03	0.05	0.11	0.17	0.18
Total Shareholders' Equity	9M	10.71M	10.8M	14.03M	15.24M	23.98M	28.82M
Common Stock	20K	20K	6.75K	6.75K	6.75K	7.8K	7.83K
Retained Earnings	4.87M	7.54M	9.6M	11.89M	14.41M	16.93M	20.02M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	461.44K	1.02M	1.11M	2.06M	740.29K	606.52K	2.04M
Minority Interest	0	0	0	0	0	0	-262.72K

Cash Flow

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Cash from Operations+	-2.39M	-1.33M	2.5M	5.84M	1.58M	3.11M	-1.21M
Operating CF Margin %	-0.11%	-0.07%	0.15%	0.28%	0.08%	0.16%	-0.05%
Operating CF Growth %	-	0.45%	2.89%	1.33%	-0.73%	0.97%	-1.39%
Net Income	3.68M	3.65M	2.21M	2.63M	2.71M	2.88M	3.42M
Depreciation & Amortization	368.26K	344.04K	329.91K	346.61K	362.6K	225.9K	346.13K
Stock-Based Compensation	0	0	0	0	0	0	0
Deferred Taxes	0	-30.36K	-77.92K	-1.66K	-86.02K	89.6K	36.33K
Other Non-Cash Items	569.69K	5.47M	80.05K	-91.31K	28.94K	113.48K	-89.93K
Working Capital Changes	-7.01M	-5.32M	-34.86K	2.96M	-1.43M	-200.81K	-4.92M
Change in Receivables	-3.97M	-2.21M	1.12M	3.08M	333.66K	-376.08K	-3.91M
Change in Inventory	-1.77M	248.34K	-1.37M	458.61K	-504.39K	1.56M	80.31K
Change in Payables	0	-2.79M	425.9K	-369.08K	-810.34K	-646.89K	-499.57K
Cash from Investing+	1.96M	126.94K	-1.96M	-1.07M	-120.9K	-7.73M	-9.51M
Capital Expenditures	-187.68K	-73.33K	-142.32K	-42.88K	-40.17K	-113.94K	-144.95K
CapEx % of Revenue	0.01%	0%	0.01%	0%	0%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	2.15M	54.85K	-2.1M	-215.03K	364.43K	10.14K	-978.93K
Cash from Financing+	-3.19M	2.36M	-343.91K	-2.87M	121.86K	6.91M	11.65M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	-3.19M	2.36M	11.42K	-103.88K	121.86K	-5.34M	4.48M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-2.58M	-1.4M	2.36M	5.8M	1.54M	2.99M	-2.33M
FCF Margin %	-0.12%	-0.07%	0.15%	0.28%	0.08%	0.15%	-0.1%
FCF Growth %	-	0.46%	2.69%	1.46%	-0.73%	0.94%	-1.78%
FCF per Share	-0.01	-0.00	0.01	0.02	0.01	0.02	-0.01
FCF Conversion (FCF/Net Income)	-0.65x	-0.36x	1.13x	2.22x	0.58x	1.08x	-0.33x
Interest Paid	0	0	136.55K	68.78K	0	5.32K	239.37K
Taxes Paid	0	0	522.11K	302.25K	47.44K	142.73K	205.37K

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	40.9%	37.02%	20.51%	21.2%	18.5%	14.68%	14%
Return on Invested Capital (ROIC)	35.78%	32.23%	15.08%	17.83%	15.36%	13.61%	10.26%
Gross Margin	36.62%	36.88%	33.95%	30.64%	32.3%	34.23%	40.43%
Net Margin	17.61%	17.91%	13.62%	12.67%	14.1%	14.52%	15.64%
Debt / Equity	0.08x	0.27x	0.25x	-	-	0.17x	0.41x
Interest Coverage	-	192.76x	20.95x	277.23x	-	-	-
FCF Conversion	-0.65x	-0.36x	1.13x	2.22x	0.58x	1.08x	-0.33x
Revenue Growth	-	-2.61%	-20.49%	28.22%	-7.58%	3.29%	18.57%

Frequently Asked Questions

Valuation & Price

Jin Medical International Ltd. (ZJYL) has a price-to-earnings (P/E) ratio of 6.1x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Jin Medical International Ltd. (ZJYL) reported $43.0M in revenue for fiscal year 2024. This represents a 105% increase from $20.9M in 2018.

Jin Medical International Ltd. (ZJYL) grew revenue by 18.6% over the past year. This is strong growth.

Yes, Jin Medical International Ltd. (ZJYL) is profitable, generating $4.7M in net income for fiscal year 2024 (15.6% net margin).

Dividend & Returns

Jin Medical International Ltd. (ZJYL) has a return on equity (ROE) of 14.0%. This is reasonable for most industries.

Jin Medical International Ltd. (ZJYL) had negative free cash flow of $0.6M in fiscal year 2024, likely due to heavy capital investments.